Rafferty Asset Management LLC Has $3.22 Million Stake in Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Rafferty Asset Management LLC reduced its holdings in Ultragenyx Pharmaceutical by 12.3%, now holding approximately 88,812 shares valued at $3.2 million.
• Ultragenyx reported a quarterly earnings per share of ($1.17), surpassing estimates, with revenue of $166.50 million, a 13.2% increase year-over-year.
• Analysts have a consensus rating of "Moderate Buy" for Ultragenyx, with price targets ranging from $34.00 to $105.00, reflecting significant optimism about the company's future.

Rafferty Asset Management LLC cut its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 12.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 88,812 shares of the biopharmaceutical company's stock after selling 12,481 shares during the quarter. Rafferty Asset Management LLC owned about 0.09% of Ultragenyx Pharmaceutical worth $3,216,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in RARE. GAMMA Investing LLC grew its stake in Ultragenyx Pharmaceutical by 76.2% during the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 323 shares during the last quarter. ANTIPODES PARTNERS Ltd purchased a new stake in Ultragenyx Pharmaceutical during the 1st quarter worth approximately $57,000. Headlands Technologies LLC purchased a new stake in Ultragenyx Pharmaceutical during the 1st quarter worth approximately $59,000. Covestor Ltd grew its position in shares of Ultragenyx Pharmaceutical by 86.8% in the first quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company's stock valued at $62,000 after purchasing an additional 795 shares in the last quarter. Finally, GF Fund Management CO. LTD. purchased a new position in Ultragenyx Pharmaceutical in the fourth quarter worth approximately $82,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock traded down $0.34 during trading on Monday, reaching $29.96. 1,340,019 shares of the company's stock were exchanged, compared to its average volume of 1,472,288. The company's 50-day moving average is $30.83 and its two-hundred day moving average is $35.06. The firm has a market cap of $2.89 billion, a price-to-earnings ratio of -5.42 and a beta of 0.21. Ultragenyx Pharmaceutical Inc. has a 52-week low of $25.81 and a 52-week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.27) by $0.10. The business had revenue of $166.50 million for the quarter, compared to analyst estimates of $161.37 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The company's revenue for the quarter was up 13.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.52) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insiders Place Their Bets

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the company's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the completion of the sale, the director owned 15,344 shares in the company, valued at approximately $573,712.16. This represents a 13.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.50% of the company's stock.

Analyst Upgrades and Downgrades

RARE has been the topic of a number of research reports. Morgan Stanley decreased their price target on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, July 14th. Canaccord Genuity Group cut their price target on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. HC Wainwright upgraded Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 price target on the stock in a research note on Monday, July 28th. Cantor Fitzgerald dropped their price objective on Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating on the stock in a report on Wednesday, August 6th. Finally, Wedbush lowered their price target on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a report on Monday, July 14th. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $81.50.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.